Predictive Value of Circulating Renalase for Left Ventricular Hypertrophy in Non-Dialysis CKD Patients
Keywords:
Biomarkers, Hypertrophy, Kidney diseases, Left ventricle, Renalase, Ventricular remodelingAbstract
Background: Chronic kidney disease (CKD) is a global health burden strongly associated with cardiovascular morbidity and mortality. Left ventricular hypertrophy (LVH), a hallmark of cardiac remodeling in CKD, is a major predictor of heart failure and sudden cardiac death. Current biomarkers fail to capture early remodeling risk adequately, underscoring the need for novel predictors. Objective: To evaluate serum renalase levels in non-dialysis CKD patients (stages 3–5) and determine its predictive value for cardiac remodeling, particularly LVH. Methods: A cross-sectional study was conducted, including 89 CKD patients, 40 heart failure patients, and 37 healthy controls. Demographic, clinical, biochemical, and echocardiographic data were collected. Serum renalase was measured using ELISA. Logistic regression models and receiver operating characteristic (ROC) analyses were applied to assess the independent predictive value of renalase for cardiac remodeling. Results: CKD patients with cardiac remodeling had significantly higher renalase levels compared to those without (36.31ng/mL vs. 33.05ng/mL, p=0.009). ROC analysis yielded an AUC of 0.656, with a cutoff value of >37.64 ng/mL (sensitivity, 47.5%; specificity, 83.3%). Logistic regression confirmed renalase as an independent predictor of remodeling (adjusted OR: 1.105, 95% CI=1.036–1.178, p=0.002), alongside uncontrolled hypertension (OR=3.462, p=0.014). Conclusions: Serum renalase is independently associated with LVH in non-dialysis CKD patients and demonstrates moderate discriminative ability with high specificity. These findings highlight renalase as a promising biomarker for early cardiac risk stratification in CKD, warranting further longitudinal validation and standardization of measurement protocols.
Downloads
References
Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease – A systematic review and meta-analysis. PloS One. 2016;11(7):e0158765. doi: 10.1371/journal.pone.0158765.
Valbuena-López SC, Camastra G, Cacciotti L, Nagel E, Puntmann VO, Arcari L. Cardiac imaging biomarkers in chronic kidney disease. Biomolecules. 2023;13(5):773. doi: 10.3390/biom13050773.
Tripepi G, D’Arrigo G, Mallamaci F, London G, Tangri N, Hsu JY, et al. Prognostic values of left ventricular mass index in chronic kidney disease patients. Nephrol Dial Transplant. 2019;36(4):665-672. doi: 10.1093/ndt/gfz254.
Naderi H, Yaqoob K, Thomson R, Aksentijevic D, Petersen SE, Yaqoob M, et al. Impact of early stages of CKD with and without proteinuria on cardiac remodelling in UK Biobank cohort. Eur Heart J. 2023;44(Supplement 2). doi: 10.1093/eurheartj/ehad655.2754.
Halle MP, Kom MF, Kamdem F, Mouliom S, Fouda H, Dzudie A, et al. Cardiovascular disease burden in patients with non-dialysis dependent chronic kidney disease in Cameroon: Case of the Douala General Hospital. Open J Nephrol. 2020;10(03):171. doi: 10.4236/ojneph.2020.103017.
Stevens PE, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, et al. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4):S117-S314. doi: 10.1016/j.kint.2023.10.018.
Desir GV. Role of novel biomarkers in chronic kidney disease: Renalase. In: Berbari AE, Mancia G, (eds.), Cardiorenal Syndrome: Mechanisms, Risk and Treatment. Milano: Springer Milan; 2010. p. 309-316.
Heryć R, Cecerska-Heryć E, Serwin N, Stodolak P, Goszka M, Polikowska A, et al. Renalase, dopamine, and norepinephrine as markers for the development of hypertension in CKD patients. BMC Nephrol. 2025;26(1):200. doi: 10.1186/s12882-025-04114-2.
Cerqueira A, Quelhas-Santos J, Ferreira I, Sampaio S, Relvas M, Marques N, et al. Circulating renalase as predictor of renal and cardiovascular outcomes in pre-dialysis CKD patients: A 5-year prospective cohort study. Life (Basel). 2021;11(3). doi: 10.3390/life11030210.
Dabravolski SA, Omelchenko AV, Korchagina ER, Maltseva ON, Pavshintsev VV, Kovyanova TI. The role of renalase in cardiovascular disease: A comprehensive review of its molecular biology, genetic associations, and clinical significance. Life (Basel). 2025;15(10):1581. doi: 10.3390/life15101581.
Wang Y, Bai L, Wen J, Zhang F, Gu S, Wang F, et al. Cardiac-specific renalase overexpression alleviates CKD-induced pathological cardiac remodeling in mice. Front Cardiovasc Med. 2022;9:1061146. doi: 10.3389/fcvm.2022.1061146.
Vijayakumar A, Mahapatra NR. Renalase: a novel regulator of cardiometabolic and renal diseases. Hypertens Res. 2022;45(10):1582-1598. doi: 10.1038/s41440-022-00986-1.
Stojanovic D, Mitic V, Stojanovic M, Petrovic D, Ignjatovic A, Milojkovic M, et al. The discriminatory ability of renalase and biomarkers of cardiac remodeling for the prediction of ischemia in chronic heart failure patients with the regard to the ejection fraction. Front Cardiovasc Med. 2021;8. doi: 10.3389/fcvm.2021.691513.
Rovin BH, Ayoub IM, Chan TM, Liu ZH, Mejía-Vilet JM, Floege J. KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS. Kidney Int. 2024;105(1s):S1-s69. doi: 10.1016/j.kint.2023.09.002.
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Int Med. 2009;150(9):604-612. doi: 10.7326/0003-4819-150-9-200905050-00006.
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627-3639. doi: 10.1093/eurheartj/ehad195.
Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269-1324. doi: 10.1161/hyp.0000000000000066.
ElSayed NA, Aleppo G, Bannuru RR, Bruemmer D, Collins BS, Ekhlaspour L, et al. Diagnosis and classification of diabetes: Standards of care in diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S20-s42. doi: 10.2337/dc24-S002.
WHO. WHO Guidelines Approved by the Guidelines Review Committee. Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation. Geneva: World Health Organization. Copyright © World Health Organization 2011.; 2011.
KDIGO. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1-59. doi: 10.1016/j.kisu.2017.04.001.
Taub CC, Stainback RF, Abraham T, Forsha D, Garcia-Sayan E, Hill JC, et al. Guidelines for the Standardization of Adult Echocardiography Reporting: Recommendations From the American Society of Echocardiography. J Am Soc Echocardiography. 2025;38(9):735-774. doi: 10.1016/j.echo.2025.06.001.
Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiography. 2005;18(12):1440-1463. doi: 10.1016/j.echo.2005.10.005.
Wang Y, Bai L, Wen J, Zhang F, Gu S, Wang F, et al. Cardiac-specific renalase overexpression alleviates CKD-induced pathological cardiac remodeling in mice. Front Cardiovasc Med. 2022;9:1061146. doi: 10.3389/fcvm.2022.1061146.
Vijayakumar A, Mahapatra NR. Renalase: a novel regulator of cardiometabolic and renal diseases. Hypertens Res. 2022;45(10):1582-1598. doi: 10.1038/s41440-022-00986-1.
Wu Y, Quan C, Yang Y, Liang Z, Jiang W, Li X. Renalase improves pressure overload-induced heart failure in rats by regulating extracellular signal-regulated protein kinase 1/2 signaling. Hypertens Res. 2021;44(5):481-488. doi: 10.1038/s41440-020-00599-6.
Wang F, Li J, Xing T, Xie Y, Wang N. Serum renalase is related to catecholamine levels and renal function. Clin Exp Nephrol. 2015;19(1):92-98. doi: 10.1007/s10157-014-0951-8.
Baek SH, Cha RH, Kang SW, Park CW, Cha DR, Kim SG, et al. Circulating renalase predicts all-cause mortality and renal outcomes in patients with advanced chronic kidney disease. Korean J Internal Med. 2019;34(4):858-866. doi: 10.3904/kjim.2017.058.
Gok Oguz E, Akoglu H, Ulusal Okyay G, Karaveli Gursoy G, Yildirim T, Merhametsiz O, et al. Increased serum renalase in peritoneal dialysis patients: Is it related to cardiovascular disease risk? Nefrología. 2017;37(2):189-194. doi: 10.1016/j.nefroe.2017.05.003.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 )
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Published by Al-Rafidain University College. This is an open access journal issued under the CC BY-NC-SA 4.0 license (https://creativecommons.org/licenses/by-nc-sa/4.0/).
